drugset / Trial / NCT02580617
A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn' disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.
Timeline
- Start
- 2015-11-09
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALLO-ASC | Cell therapy | 5e+07 cells | Intravenous |
| Subject | ALLO-ASC | Cell therapy | 7.5e+07 cells | Intravenous |
| Subject | ALLO-ASC | Cell therapy | 1e+08 cells | Intravenous |